Overview

Specified Drug Use-results Survey of Betanis Tablets for Patients With Coexisting Cardiovascular Disease

Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
This purpose of this study is to investigate the effects of mirabegron on the cardiovascular system in patients with overactive bladder with current or a history of cardiovascular disease.
Details
Lead Sponsor:
Astellas Pharma Inc
Treatments:
Mirabegron